Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PEGPH20 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in untreated stage IV hyaluronan-high pancreatic ductal adenocarcinoma
MOH_2017-03-15_000229Phase 3Recruiting
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing PEGPH20 + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoint: Primary endpoint not reported. Started Mar 2016; status: recruiting.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2017-03-15_000229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-15_000229.